A bstract
Human mesenchymal stem cells (MSC) have attracted much attention for tissue regeneration including repair of non-healing bone defects. Heterogeneity of MSC cultures and considerable donor variability however, still preclude standardised production of MSC and point on functional defi cits for some human MSC populations. We aimed to identify functional correlates of donor-dependency of bone formation in order to develop a potency assay predicting the therapeutic capacity of human MSC before clinical transplantation. MSC from 29 donors were characterised in vitro and results were correlated to bone formation potency in a beta-tricalcium-phosphate (β-TCP)-scaffold after subcutaneous implantation into immunocompromised mice.
In contrast to osteogenic in vitro differentiation parameters, a doubling time below 43.23 hours allowed to predict ectopic bone formation at high sensitivity (81.8%) and specifi city (100%). Enriched conditions adapted from embryonic stem cell expansion rescued bone formation of inferior MSC populations while growth arrest of potent MSC by mitomycin C abolished bone formation, establishing a causal relationship between neo-bone formation and growth. Gene expression profi ling confi rmed a key role for proliferation status for the bone forming ability suggesting that a rate limiting anabolism and open chromatin determined and predicted the therapeutic potency of culture-expanded MSC. Proliferation-based potency testing and switch to enriched expansion conditions may pave the way for standardised production of MSC for bone repair.
Introduction
Mesenchymal stem cells (MSC) support the homeostasis of mesenchymal tissues and their trophic and mesengenic activities bear a high therapeutic potential for tissue regeneration. Refl ecting the complexity of the stromal system in bone marrow, MSC populations expanded from marrow aspirates are heterogeneous in nature with the exact composition depending on the donor (Rickard et al., 1996; Majors et al., 1997; Muschler et al., 2001) , the individual aspirate (Lazarus et al., 1997; Muschler et al., 1997; Phinney et al., 1999; Muschler et al., 2001; Hernigou et al., 2006) , applied isolation methods and expansion conditions, the latter of which differ largely among investigators (Phinney, 2002; Shahdadfar et al., 2005; Sotiropoulou et al., 2006; Mannello and Tonti, 2007; Wagner and Ho, 2007) . Cloned populations of MSC demonstrate that only part of the cells is multipotent while the remaining population shows varied phenotypes (Russell et al., 2010) . Increasing interest in the clinical use of MSC, however, demands standardised methods to produce cell populations of high regeneration capacity and accurate control of their therapeutic potential (Phinney, 2007; Caplan, 2009; Tarte et al., 2010) . This includes the necessity to determine the therapeutic potency of every MSC population by an adequate assay before it may be transplanted.
MSC-based tissue engineering approaches have attracted attention in the context of bone repair since they were successfully used to bridge large bone defects in animal models (Bruder et al., 1998a; Bruder et al., 1998b) . Bone formation by bone marrow-derived human MSC is, however, less robust compared to other species according to classical tests of heterotopic bone formation (Krebsbach et al., 1997) , which further document a donor variability for human MSC populations (Mendes et al., 2002; Mendes et al., 2004; Siddappa et al., 2007; Siddappa et al., 2008; Matsushima et al., 2009 ). Parameters such as age, gender, medication or disease of the donor and the location of bone marrow harvest (Muschler et al., 2001; Stenderup et al., 2003; McLain et al., 2005; Siddappa et al., 2007) were considered as reasons for this undesired character of human MSC, pointing out functional defi cits for human MSC populations from some donors compared to others. On the other hand, expansion conditions are likely to infl uence the overall cell composition (Martin et al., 1997; Muraglia et al., 1998; Kuznetsov et al., 2000) and the fi tness of cells at the time of transplantation may strongly infl uence their actual bone forming potency in vivo. It is conceivable that patients treated with suboptimal MSC populations may develop poorer regeneration results or that cell-based treatment may even fail in spite of high www.ecmjournal.org P Janicki et al. Prediction of bone formation of human MSC costs infl icted with this therapy. So far no tests are available to predict the potency of individual bone marrow-derived MSC populations to form bone in vivo in order to pave the way for standardised clinical use of MSC in bone repair. In addition, no rate-limiting cellular or molecular correlates of in vivo bone formation have been identifi ed for human MSC. While many studies addressed donor variations regarding growth and osteogenic in vitro potential of human MSC (Jaiswal et al., 1997; Digirolamo et al., 1999; Phinney et al., 1999; Mendes et al., 2004; Siddappa et al., 2007) , and predictors of successful in vitro osteogenesis of MSC have recently been reported (Platt et al., 2009; Pietila et al., 2010) , no irrefutable positive correlation between in vitro parameters or molecular signatures of bone marrow-derived human MSC populations and in vivo bone formation have been identifi ed.
This study was undertaken to unravel rate-limiting cellular and molecular aspects underlying the ectopic bone formation ability of human MSC. This test requires the use of a scaffold and a recently characterised beta-tricalciumphosphate (β-TCP) was chosen, since it demonstrated superior potency compared with a hydroxyapatite/ tricalcium-phosphate (HA/TCP) ceramic (Janicki et al., 2010) . In order to extract predictors applicable as clinically relevant potency assays, our approach was to expand human MSC from a large cohort of donors under standardised conditions. Donor characteristics, growth properties, in vitro differentiation potential and gene expression profi le of each MSC population were determined and correlated to the in vivo bone formation. We identify a rate-limiting doubling time and molecular signature of open chromatin as highly predictive for in vivo bone formation, and establish a causal relationship between bone formation and growth allowing the rescue of inferior MSC populations for therapeutic use.
Materials and Methods

Cell isolation and cultivation
Human bone marrow cells were aspirated from the iliac crest or femur of 29 donors. Informed consent was obtained from all individuals and the study was approved by the local ethics committee. MSC were isolated from fresh bone marrow samples as described previously (Dickhut et al., 2009) . In short, density gradient isolated mononuclear cells were seeded in expansion medium (High-glucose Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Karlsruhe, Germany), 2 % foetal calf serum (FCS, Biochrom, Germany), 40 % MCDB201, 0.02 μM dexamethasone, 0.1 mM ascorbic acid 2-phosphate, 2 % insulin-transferrin-sodium selenite media supplement (all Sigma-Aldrich, Steinheim, Germany), 100 U/mL penicillin and 100 μg/mL streptomycin (Biochrom, Berlin, Germany), 10 ng/mL recombinant human epidermal growth factor and recombinant human platelet-derived growth factor BB (both Strathmann Biotech, Hamburg, Germany) (Reyes et al., 2001 ) at a density of 5 x10 5 cells/cm 2 . Where indicated, mononucleated cells (n = 5 donors) were simultaneously seeded at a density of 1.25 x10 5 cells per cm 2 into 0.1 % gelatin-coated fl asks in an embryonic stem cell (ES) medium (DMEM, 12.5 % FCS, 2 mM L-glutamine, 1 % non essential amino acids, 0.1 % 2-mercaptoethanol (Invitrogen), 100 U/mL penicillin, 100 μg/mL streptomycin, 4 ng/mL human fi broblast growth factor-2 (Active Bioscience, Hamburg, Germany)). 33 % of the ES medium was conditioned for 48 h by primary mouse embryo fi broblasts (PMEF-NL, Millipore, Molsheim, France). Standard culturing conditions were used (37 °C, 6 % CO 2 ) and the medium was changed twice a week. For culturing MSC were replated at a density of 4-6 x10 3 cells/cm 2 . Cell surface marker expression profiles and the multipotency were standardly determined for MSC populations, as described previously (Winter et al., 2003; Dickhut et al., 2009) . Depending on the experimental setting, cells from passage 1, 2, 3 or 5 were used. For inhibition of cell proliferation at passage 2 (n = 4 donors) cells were treated for 2 h with medium containing 20 μg/ mL mitomycin C (Sigma-Aldrich) and washed twice with PBS. Untreated and mitomycin C-treated MSC were then incubated with 1 % trypsin/ethylenediaminetetraacetic acid (Biochrom) solution, harvested, centrifuged, resuspended in PBS and used for experiments like WST-1 assay (replated in culture medium), osteogenesis in vitro (replated in induction medium) or ectopic transplantation (seeded on β-TCP granules).
Heterotopic in vivo bone formation assay
To allow broad characterisation of MSC from the fi rst 20 donors in multiple assays at the time of transplantation, about 3 x10 7 cells were required from each donor. This number was usually reached at passage 3 (P3) allowing all assays to be started including β-TCP/MSC transplantation to assess heterotopic bone formation after 8 weeks.
Phase-pure (>95 %) β-TCP (Ca 3 (PO 4 ) 2 ) granules (0.5-0.7 mm, RMS Foundation, Bettlach, Switzerland) with a porosity of 60 %, macropores of 100-500 μm and not specifi ed micropores were sterilised for 6 h at 120 °C, and 10 mg granules were mixed with 1 x10 6 MSC and fi brin glue as described previously (Janicki et al., 2010) . Seeding efficiency was 98-99 % according to counting of MSC remaining after a fi rst washing step of the constructs. Freshly prepared three-dimensional constructs consisting of β-TCP and MSC (2-4 per donor, n = 29 donors) were transplanted for 8 weeks into paravertebral subcutaneous pouches of 6-8 week old male severe combined immunodefi ciency (SCID) mice (n = 45) (Charles River, Sulzfeld, Germany). According to the number of MSC populations cultured simultaneously, β-TCP/MSC constructs of one or two donors were transplanted into one animal. Two to four subcutaneous pouches were prepared per mouse and one construct per pouch was implanted. All procedures were performed according to the European Laboratory Animal Science guidelines. The experimental protocol was approved by the local animal experimentation committee (35-9185.81G-95/06). All animals survived the experimental period of 8 weeks.
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Histological evaluation β-TCP/MSC explants were fi xed in Bouin´s solution for 2 days providing fi xation and partial decalcifi cation in one step (Kuznetsov et al., 2000) . Further, explants were dehydrated using graded alcohol series and embedded in paraffi n. Sections were stained with haematoxylin and eosin (H&E, Chroma, Münster, Germany). Human cells were identifi ed by detection of human-specifi c genomic Alu repeats using a digoxygenin-labelled probe, as previously described (Steck et al., 2010) . Briefl y, paraffi n sections were deparaffi nised, rehydrated in alcohol and digested in 50 ng/mL proteinase K (Fermentas, St. LeonRot, Germany). After washing with PBS, sections were treated with 0.1 M triethanolamine hydrochloride pH 8 (Sigma-Aldrich) in 0.25 % acetic acid and pre-hybridised in hybridisation buffer containing 4x saline-sodium citrate (SSC), 1x Denhardt's solution, 5 % dextrane sulphate, 50 % deionised formamide, 100 μg/mL salmon sperm DNA and aqua bidest. Hybridisation buffer was replaced by fresh hybridisation buffer containing 0.2 ng/ μL dioxigenin-labelled probe, sections were denaturated and immediately cooled. Hybridisation was carried out for 16 h in a wet chamber. Sections were washed twice in 2x SSC and twice in 0.1x SSC. Positive signals were detected by using anti-digoxygenin alkaline phosphataseconjugated Fab fragments and nitro-blue-tetrazolium/5-Bromo-4-chloro-3-indolyl-phosphate (Roche, Mannheim, Germany) as substrate. Sections were counterstained with fast red (Chroma).
Osteogenic in vitro differentiation of human MSC
Per donor (n = 29 donors) 3.5 x10 4 MSC per well were seeded in quadruplicates into 24-well plates and were incubated with high-glucose DMEM supplemented with 10 % FCS, 0.1 μM dexamethasone, 0.17 mM ascorbic acid 2-phosphate, 10 mM β-glycerophosphate (Sigma-Aldrich) and 1 % penicilli n/streptomycin. At four time points (day 1, 7, 14, 21) two wells each were used for assessment of alkaline phosphatase (ALP) enzyme activity while two wells served to quantify mineralisation using alizarin red S staining.
Alkaline phosphatase activity assay Cells were lysed with 1 % triton X-100 detergent (SigmaAldrich) in PBS, scraped off the plate and stored at -80 °C (two wells per donor and time point). ALP activity was assessed in duplicates by diluting two 50 μL samples with 50 μL ALP buffer (0.1 M glycine, 1 mM MgCl 2 , 1 mM ZnCl 2 , pH 10.4) each before incubation with 100 μL ALP buffer plus 1 mg/mL p-nitrophenylphosphate (p-NPP). The conversion to p-nitrophenol (p-NP) was measured spectrophotometrically at 405/490 nm after 1 h of incubation. Total protein concentration was determined by the Micro BCA TM Protein Assay Reagent Kit (Pierce Biotechnology, Rockford, IL, USA) according to manufacturer's instructions. The amount of p-NP divided by the amount of total protein normalised the specifi c amount of ALP.
Alizarin red S staining for calcifi cation Cells were fi xed with 70 % ethanol and stained with 0.5 % alizarin red S (Chroma) (two wells per donor and time point). Monolayers were treated with 10 % hexadecetylpyridinium-chloride-monohydrate (CPC) and the eluted solution of each well was measured spectrophotometrically in duplicates at 570 nm. The amount of CPC was divided by the amount of total protein to normalise for cell quantity.
Evaluation of generation time
Generation time was calculated for each MSC donor population (n = 29) using the following formula: G = (log2 x T) / (logY -logX). G stands for generation time [hours] , T for time in culture per passage [hours] , Y for cell number at harvesting time point, X for cell number at seeding time point.
H-thymidine proliferation assay
To analyse the proliferation rate, 4 x10 3 MSC were seed ed into 96-wells in triplicates in expansion medium (n = 29 donors). After 24 h, medium was replaced by fresh medium containing 0.25 μCi of [methyl- 3 H]-thymidine (GE Healthcare, München, Germany) per well. After additional 18 h cells were washed, lysed with 1 % triton X-100 and transferred into tubes containing 2 mL scintillation cocktail (Perkin Elmer, Waltham, MA, USA). Radioactivity was measured by a WinSpectral 1414 Liquid Scintillation Counter (Perkin Elmer).
WST-1 assay
To analyse the vitality, 4 x10 3 MSC were seeded into 96-wells in triplicates in expansion medium (n = 2 donors). Medium was replaced 24 h after seeding by 90 μL fresh medium and supplemented with 10 μL of 4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1, Roche, Mannheim, Germany) per well. MSC were incubated for 1 h at 37 °C according to manufacturer's instructions and the cleavage of WST-1 to formazan was measured spectrophotometrically at 450 nm.
Microarray analysis
Total RNA was isolated out of 0.6-3 x10 6 expanded MSC (n = 8 populations with and n = 8 populations without the ability to form ectopic bone) at the time point of transplantation using RNeasy Mini kit according to manufacturer´s instructions (Qiagen, Hilden, Germany). The microarray analysis (Illumina Human Sentrix, Human Ref_8 v3.0) was performed at the Genomic & Proteomics Core F acility of the German Cancer Research Centre in Heidelberg, Germany. Briefl y, cDNA was synthesised from 0.5 μg of total RNA, followed by an amplifi cation/ labelling step to synthesise a biotin-labelled cRNA. After purifi cation and quality control, 0.75 μL of the labelled probes were hybridised to the BeadChips consisting of 24.495 transcripts and transcript variants. Data analysis was done by normalisation of the signals using the P Janicki et al.
Prediction of bone formation of human MSC quantile normalisation algorithm without background subtraction, and differentially regulated genes were defi ned by calculating the standard deviation differences of a given probe in a one-by-one comparison of both groups. Cluster analysis was adopted to fi nd differences between MSC with and without bone forming capability. Log transformed signal intensities were calculated and submitted to average linkage hierarchical clustering using the Cluster and Treeview software (Eisen et al., 1998) . Signifi cantly different expressed genes were annotated using open source Database for Annotation, Visualisation and Integrated Discovery (DAVID v6.7 (Dennis et al., 2003; Huang et al., 2009) ).
Quantitative real-time polymerase chain reaction First-strand cDNA was synthesised from 2 μg of total RNA using Omniscript reverse transcriptase (0.2 U/μL) and oligo(dT) primers (1 μM) (Qiagen) according to the manufacturer's instructions. The cDNA was quantifi ed with a LightCycler 3 using LightCycler FastStart DNA Master SYBR Green I Kit (both Roche Diagnostics) according to the manufacturer's instructions. The following primers were used: β-actin:
HIST2H2AA3: 5´-TACATGGCTGCGGTCCTC-3´, 5´-GGAGGTGACGAGGGATGAT-3´. The β-actin signal was used for normalisation.
Statistical analysis
Differences in outcome parameters were assessed by non-parametric two-tailed Mann-Whitney U test and a p ≤ 0.05 was considered signifi cant. For correlations between two categorial variables, the non-parametric Spearman´s rank correlation (r s ) was applied. To refl ect the degree of linear re lationship between two variables, the Pearson´s correlation (r p ) was adopted. To determine thresholds for ALP values and generation time in regard to bone formation, the receiver-operating characteristic (ROC) analysis was performed calculating sensitivity/ specifi city pairs by varying the decision threshold levels over the entire range of results (Metz et al., 1973; Zweig and Campbell, 1993) . Data analysis was performed with SPSS for Windows 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Donor variability of heterotopic bone formation
While explants derived from the same donor showed little variation in neo-bone formation, a huge variability was evident for constructs from different donors. Overall, MSC from 11 out of 20 donors had formed bone ( Table 1 . Donor characteristics and MSC in vitro parameters in relation to bone formation listed by increasing generation time.
*at time point of implantation, **during osteogenic in vitro differentiation, ' = not included in gene expression analysis since used for experiments in Table 2 , --------------optimal threshold (43.23 h/PD).
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in bone formation ( Fig. 1B) (mean age 51.3, SEM ±6.45, Table 1 ). Osteoblast-like cells depositing bone in the pores of the β-TCP granules were of human origin (Fig. 1A , inset). Only few or no human cells were identifi ed within the fi brous tissue of β-TCP/MSC constructs from the non-bone forming group (Fig. 1B, inset ). This indicated that MSC which were incapable to form bone migrated away from the constructs or died. Vascular structures were apparent in all constructs independent of bone formation. MSC-free β-TCP granules or carrier-free MSC never revealed bone structures (data not shown). There was no correlation between the site of bone marrow harvest or the pathology of donors, like osteoarthritis or other diseases, and the bone forming potency of the MSC.
Correlation of in vitro osteogenesis with in vivo bone formation
In parallel to transplantation, MSC populations of 20 donors were subjected to osteogenic in vitro conditions for 21 days in culture. Osteogenesis resulted in a timedependent increase of ALP activity and calcium deposition for all donor MSC. Mineralisation was not signifi cantly different between MSC groups with or without bone formation (p ≤ 0.112) (Fig. 1C) . ALP activity revealed a high donor variability during osteogenic in vitro induction with bone-forming MSC populations reaching signifi cantly higher ALP values at day 7 (p = 0.004), day 14 (p = 0.002) and day 21 (p = 0.001) (Fig. 1D ). Thus, a strong positive correlation (r s ROC analysis was applied in order to determine an optimal ALP threshold level which would best predict bone formation in our model. The optimal decision threshold for peak ALP values was 3.34 ng substrate/minute and μg protein.
All MSC populations with values below this cut-off level failed to form bone (100.0 % specifi city), while all bone forming samples except one (donor 11, Table 1 ), had maximal ALP values above this threshold, corresponding to a test sensitivity of 90.9 %.
Correlation of growth rate with bone formation
In contrast to the outcome of an in vitro osteogenic assay, growth parameters are known before transplantation of MSC and are, thus, attractive as possible predictors of bone formation capacity in a clinical setting. MSC samples forming bone revealed a signifi cantly higher 3 H-thymidine incorporation into DNA (2.58-fold, p = 0.002) ( Fig. 2A) and thus a higher proliferation rate than MSC incapable to form bone. Bone forming MSC had a signifi cantly shorter mean generation time (36.16 h per population doubling (h/PD), SEM ±2.7, p ≤ 0.001) than MSC without bone formation (87.49 h/PD, SEM ±15.1) (Fig. 2B ) revealing a strong correlation between generation time and bone formation (r s = -0.810, p ≤ 0.001). The optimal decision level for prediction of bone formation based on generation time was 43.23 h/PD according to ROC analysis (dashed line, Table 1 ). All MSC failing to form bone grew more slowly than this threshold (100 % specifi city) while all but 2 donor populations forming bone were faster than this threshold (donor 11 and 13, Table 1 ) yielding a test sensitivity of 81.8 %. Thus, at the chosen conditions, doubling time at the day of transplantation would have correctly predicted in vivo bone formation capability of 18 out of 20 donors without any false positives.
Since faster growing MSC populations reached P3 earlier than cells growing more slowly, bone forming MSC were transplanted after a signifi cantly shorter time in culture (mean 15.91 days, SEM ±0.61) than MSC of the other group (20.89 days, SEM ±1.12, p ≤ 0.001). All MSC cultured for 17 days or less formed bone (Table 1) while MSC expanded for more than 19 days never formed bone under our expansion conditions. Age and ALP activity correlated signifi cantly with the proliferation rate of MSC ( Fig. 2C-D) demonstrating that these parameters represent no independent determinants of bone forming ability.
Serial passaging and in vivo bone formation
We next challenged the determined decision levels for ALP-based and proliferation-based prediction by testing the bone forming ability of four MSC populations during serial passaging (Table 2 ). Generation time of each MSC population increased with every passage and bone formation capacity declined in parallel. While all P1 cells formed ectopic bone (Fig. 2E , closed symbols), one MSC population had lost its bone formation ability at P3 while at P5 all four MSC populations were negative (Fig. 2E, open  symbols) . The generation time of about 43 h/PD extracted before, again, correctly predicted bone formation for 10 out of these 12 transplanted MSC populations (P1, P3, P5 from four donors each) with no false positive results. Table 2 . Generation time and maximum ALP activity of MSC during serial passaging (P1-P5).
*At time point of implantation, **During osteogenic in vitro differentiation, bold = samples that showed bone formation in vivo.
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Prediction based on in vitro ALP activity, however, did not pass this test. Although ALP activity was high in all P1 populations and decreased at P3, it increased again at P5 reaching the highest values for cells without bone forming ability (Table 2) . Thus, in contrast to generation time, the in vitro ALP response to osteogenic induction turned out to be no robust predictor of heterotopic bone formation.
Modulation of proliferation rate can rescue in vivo bone formation
In order to look for a causal relationship between mitotic activity and heterotopic bone formation capacity, we tried to rescue inferior MSC populations by improved expansion under enhanced conditions. Slower versus faster growing MSC were produced from the same marrow aspirates by expansion in culture medium versus enriched conditions adapted from embryonal stem (ES) cell protocols (donor 21-25, Table 3 ). MSC in ES-medium incorporated on average 8.5-fold more 3 H-thymidine (not shown) and revealed 1.58-fold shorter generation times (Table 3) compared to MSC under standard expansion. At the same time point (near confl uence at P2, day 11-18, depending on the donor) both MSC populations from each donor were harvested and transplanted. While all ES-medium expanded MSC grew faster than 43 h/PD and formed heterotopic bone, the corresponding standard cultures remained above 43 h/PD and 4 of these 5 MSC populations could not form bone as predicted according to generation time. Altogether this demonstrated that enhancing the proliferation rate rescued bone formation of inferior MSC suggesting a causal relationship between proliferation rate and in vivo bone formation.
No bone formation without proliferation
To decide whether growth is a prerequisite for bone formation, human MSC (donor 26-29, aged 17-79 years) with a permissive generation time at P2 were treated for 2 h with the mitotic inhibitor mitomycin C which irreversibly blocks DNA synthesis and inhibits proliferation. DNA synthesis dropped to 12 % by this treatment within 18 h (Fig. 3A , n = 4 donors) while values for cell metabolism were reduced by half (Fig. 3B , n = 2 donors), demonstrating that mitomycin C-treated cells were alive but unable to proliferate. After ectopic transplantation of constructs consisting of 10 mg β-TCP and either treated or untreated MSC (1x 10 6 cells, P2), respectively, none of the mitomycin C-treated MSC formed bone, while the corresponding untreated MSC (generation times 21.89 to 34.43 h/PD) all formed bone. During osteogenic in vitro induction, however, all mitomycin C-treated cells were able to deposit a mineralised matrix (data not shown).
Molecular correlates of in vivo bone formation
In order to extract molecular markers as potential predictors, gene expression profi ling was performed for 16 MSC populations from Table 1, half of which had shown bone formation capability in P3. Cluster analysis identifi ed a group of 4 closely related MSC populations which had formed bone and 3 closely related MSC populations which did not form bone. Gene signatures of these two groups differed by 311 genes at signifi cance level. When this selection of genes was used for clustering of all 16 samples (Fig. 4A ) two groups of 8 samples each were obtained in which all bone forming MSC were separated from all nonbone forming cells except one wrong sample in each group. 
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Of the 311 differentially expressed genes, 230 were higher expressed in bone-forming MSC (1.8-fold to 34.9-fold) including many cell cycle-associated genes like CDC20, CDCA7, CDC45, CDCA5 and the cyclins CCNB2, CCNA2, CCNE2, CCNF associated with cell proliferation (Table 4 ). Functional annotation of these genes by the DAVID program (Dennis et al., 2003; Huang et al., 2009 ) revealed mitosis, cell division, DNA replication and related pathways as main biological functions.
In the group of MSC that did not form bone, 81 genes were higher expressed. These included genes of the histone clusters HIST1H1C, HIST1H4H, HIST2H2AC, HIST2H2AA3, and molecules relevant for the formation of nucleosomes, dense chromatin, or capable of protein-DNAcomplex formation. Some genes were associated with apoptosis (Table 5 ). Selected transcripts were confi rmed by RT-PCR to have a signifi cantly different expression level between the bone and not bone forming group (Fig.  4B ). In summary, molecular analysis corroborated cell growth and an open chromatin as main determinant of in vivo bone formation making further investigation into molecular prediction assays promising.
Discussion
We here present a strategy to predict the heterotopic bone forming ability of human MSC populations in a β-TCP scaffold by a surprisingly simple potency test relying on determination of the generation time of MSC at the time of transplantation. Our study, for the fi rst time, establishes a causal relationship between proliferation ability and heterotopic in vivo bone formation potency of human MSC and identifi es a rate limiting proliferative activity as crucial for the success of neo-bone formation. A threshold set for generation time (43.23 h) at the time of MSC transplantation allowed, at our expansion conditions, to correctly predict the in vivo outcome of more than 20 donor populations with high specifi city and sensitivity. This threshold proved also valuable when MSC were expanded for different passages and under altered expansion conditions. Proliferation rate also predicted the loss of heterotopic bone formation with increasing passage seen here in agreement with a recent study (Agata et al., 2010) suggesting that time in culture is an alternate growth-dependent parameter of bone formation. Overwhelming molecular evidence from genome-wide transcriptome analysis confi rmed growth and an open chromatin status as the major functional correlates of heterotopic bone formation. Altogether our data suggest that, in order to be successful, MSC have to be transplanted in a time window in which suffi cient cells show high anabolism as major prerequisites for trophic and osteogenic activity at the site of transplantation. Beside its simplicity, a sensitivity of about 80 % at a specifi city of 100 % under our conditions makes this assay quite attractive in the context of clinical use.
Why is growth such a dominant parameter in a heterotopic osteogenic differentiation model where osteoinductive growth factors, appropriate mechanical Real-time PCR analysis confi rmed the expression differences of two selected genes obtained by the array analysis. CDC20 was higher expressed (*p = 0.015) in the bone forming group, whereas HIST2H2AA3 was higher (*p = 0.001) in the MSC group without bone formation. Bars represent standard error of the mean. Table 4a . Genes with signifi cantly higher expression in expanded MSC capable to form bone after subcutaneous transplantation in SCID mice (part 1). Table 4e . Genes with signifi cantly higher expression in expanded MSC capable to form bone after subcutaneous transplantation in SCID mice (continued -part 5). Table 5 . Genes with signifi cantly higher expression in expanded MSC which were not able to form bone after subcutaneous transplantation in SCID mice. (Jensen et al., 2006; Okuda et al., 2007) . Unfortunately, it was not possible to document and correlate the degree of resorption of β-TCP to proliferation rate, because the radio-opaque shadows of newly built bone obtained by quantitative micro-computed tomography could not be discriminated from those of the ceramic. Remarkably, enhanced conditions adapted from embryonal stem cell expansion were able to rescue the bone forming ability of inferior MSC in agreement with an enhanced proliferation rate, extending the permissive window to later time points in culture. Overall it is tempting to speculate that, in general, a high anabolism may be a rate limiting parameter crucial for therapeutic applications in which the trophic activity of MSC is important like in myocardial infarction. On top of this, open chromatin may be further relevant if differentiation and thus mesengenic activity is required to allow cells to contribute physically to repair tissue due to their plasticity. In contrast to this, MSC with inhibited proliferation were unable to form bone in vivo, showing again the correlation between growth and osteogenic in vivo potency. In Fig. 3 , at fi rst sight, mitomycin C-treated cells seemed to be half as vital as untreated MSC that may be caused by a toxicity of the reagent. However, these values were not normalised to the DNA content of the wells and generation time at seeding of untreated MSC suggests that cells expanded about twofold during the assay, while mitomycin C-treated MSC were unable to proliferate. Taking this into consideration, there is almost no difference in MSC vitality between both groups giving no hints on a toxicity of the chosen standard mitomycin C concentration on MSC.
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One important question is why the dominant role of growth for therapeutic potency was so far unrecognised. First, there are only a few studies which systematically addressed the donor variability of primary human MSC in the context of a desired in vivo outcome. Among studies addressing donor-dependent features of bone formation (Mendes et al., 2002; Mendes et al., 2004; Siddappa et al., 2007; De Bari et al., 2008) only two studies comprised more than 5 donors and in both a osteogenic pre-induction protocol was applied before transplantation (Mendes et al., 2002; Mendes et al., 2004) . Second, opposite to clinical application, where sorting out of inferior cell populations is not possible since the donors require a treatment, researchers frequently work only with the best cell populations leaving those of inferior growth behind. Third, investigators usually do not know the number of multipotent MSC in their starting cultures which can differ by more than 100-fold per mononuclear cell fraction according to colony-forming assays (Majors et al., 1997; Muschler et al., 2001) . Thus, some MSC populations may have already undergone 7-10 more population doublings before fi rst confl uency compared to others with seeding density being an additional parameter to infl uence the replicative potential of MSC (Phinney, 2002) . Thus, the usual "standardisation" of cultures by passage number falls short in refl ecting comparable conditions between donors and may hide this correlation unless a high number of donor populations are investigated, as done in this study.
Although a sharp threshold of around 43 h per population doubling was here suggested to separate boneforming from non-bone-forming MSC, indeed a time span of several hours existed (between 43 h and about 60 h per population doubling), within which the generation time alone could not fully predict the in vivo outcome in the heterotopic model. In single cases, non-cellular parameters related to the mouse or the transplantation procedure may have prevented bone formation as evident from gene expression profi ling of MSC from donor 10, which perfectly matched other bone forming samples in cluster analysis of gene expression (Fig. 4) , but was unable to form bone in vivo. Obviously however, at a still permissive proliferation rate between 43 and 60 h, other factors become relevant which further infl uence the degree of bone formation in vivo. Interestingly, increased overrepresentation of extracellular matrix genes was recently reported to characterise the molecular phenotype of a human MSC clone with bone-forming capacity at lower population level compared to high population level when heterotopic bone formation was lost (Larsen et al., 2010) . Since this MSC line grows indefi nitely due to stable expression of the human telomerase reverse-transcriptase (hTERT) gene, speed of proliferation may not be ratelimiting allowing extracting further predictors beyond proliferation rate like expression of dec orin or natriuretic peptide-receptor-C which were, however, not extracted in our transcriptome analysis.
Genes known as positive regulators of osteogenesis like ALP, Runx2, osteopontin, osteocalcin or bone sialoprotein P Janicki et al.
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were not signifi cantly up-regulated in our gene expression profi ling of undifferentiated MSC populations. Before transplantation, there was also no signifi cant difference regarding the expression of osteogenic genes between bone-forming MSC populations and MSC without the ability to form bone. This demonstrates that the contamination of MSC populations with osteoblasts or partly differentiated osteogenic progenitor cells, although present to some extent, was no prominent factor infl uencing bone formation. This suggests that the high proliferation rate of a large fraction of MSC in a population outcompeted the possible advantage by a fraction of cells that may already have taken the fi rst steps to become an osteoblast. The highly ordered deposition of bone towards the β-TCP scaffold pores suggests that the capacity to deposit a mineralised matrix is spatially controlled and the fi ttest MSC to achieve this may be fast proliferating rather than pre-differentiated cells. Importantly, in vitro mineral deposition did not correlate with the in vivo bone formation in our study and this disqualifi ed the standard osteogenic in vitro assay as a correlate of heterotopic bone formation ability of human MSC. This is in line with another study showing that ex vivo matrix mineralisation assays lack specifi city, may be confounded by precipitation of calcium phosphate and show surprisingly poor concordance with bone formation in vivo (Larsen et al., 2010) . Overall, this questions the usefulness of in vitro mineralisation to defi ne "multilineage capacity" of mesenchymal cell populations. In contrast to mineralisation, ALP activity during in vitro osteogenesis seemed to be a more specifi c parameter to predict the osteogenic in vivo potency of human MSC. Peak ALP values were chosen for statistical correlation since the time course of ALP up-regulation was distinct between donors, and day 21 provided not always the highest values. Our results showed that optimum in vitro ALP activity was a growth-related parameter and highlighted again the correlation to and importance of proliferation.
Altered expansion conditions will require determination of a new threshold level for generation time as predictor, and the heterotopic bone formation model applied here cannot be used to conclude about the bone formation ability of MSC in a bony defect. If bone is formed at an ectopic site in the absence of a supporting bone environment, it is however likely that the same cells will also be able to form bone orthotopically in a bony lesion. Nevertheless, observations from an adequate orthotopic model are required to decide about the importance of high proliferation rate and open chromatin for neo-bone formation in a setting closer to clinical application.
Since age-related changes were reported for human MSC (Stolzing et al., 2008) , people with inferior stem cells in bone marrow aspirates might exist. Most importantly our data promise that all aspects ensuring fast but limited expansion of MSC, like use of suffi cient MSC at start of culture, enhanced growth conditions, and careful calculation of the number of cells to be transplanted, may pave the way for promising therapeutic application of MSC from elderly donors given a successful potency testing before transplantation.
Conclusion
In conclusion, therapeutic effi ciency of MSC may strongly depend on their trophic and mesengenic "fi tness" which in our study correlated with a short generation time and, thus, high anabolism. We demonstrated that proliferation of MSC is a rate-limiting determinant of heterotopic bone formation, established a causal relationship between growth and engraftment and introduced a potency test allowing prediction of in vivo bone forming ability with high sensitivity and specifi city.
Rather than identifying unsuitable donors, we suggest that MSC have to be transplanted in a time window in which sufficient cells show high anabolism as major prerequisite for trophic and mesengenic activity.
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β-TCP/MSC-constructs, thus here a magnesium effect can be excluded.
Reviewer II: Why did mitomycin-treated cells deposit a mineralised matrix in vitro?
Authors: Mitomycin C-treated MSC were shown to be unable to proliferate on the one hand but were still vital as shown by the WST assay (see Fig. 3 ). Consequently, when cells are vital, they are able to answer to extrinsic stimuli like induction media. In our case, MSC answered to osteogenic in vitro stimuli showing that proliferation was not necessary for the deposition of calcifi ed matrix. This was in sharp contrast to the in vivo situation where the ability to proliferate was essential for successful bone formation and showed again, that the in vitro mineralisation assay is not informative about the bone forming potency of human MSC.
Reviewer II: Wouldn't it be better to use clones? Authors: We used non-clonal MSC populations to be close to the clinical situation. Cloning is unattractive since MSC clones are not stable. So after expansion of clones, one ends up with a heterogeneous cell population derived from one cell.
Reviewer II: The conclusions are based on the scaffold and have very little to do with the clinic. Please comment. Authors: Our conclusion is based on a scaffold with high osteo-permissive features which were demonstrated and compared in a previous study (Janicki et al., 2010, text reference) . Human MSC do not form ectopic bone without any scaffold. Thus, we made the decision to choose β-TCP as a matrix frequently used in orthopaedic surgery. MSC could well be transplanted in context with such granules in patients. 
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